![10](https://www.srjnews.com/wp-content/uploads/2015/06/10.jpg)
Celsion Corp. (NASDAQ:CLSN) [Trend Analysis] released that a optimistic interim data from its ongoing Phase 2 DIGNITY Trial of ThermoDox in patients by means of recurrent chest wall breast cancer. The reported five complete responses, four partial responses, and four stable disease, at the same time as local response rate in 13 patients were 69% percent. The firm aims to enroll 20 patients for the ThermoDox study in combination with mild hyperthemia. It aims plans to conduct Euro-DIGNITY trial in five countries to assess early stage breast cancer patients in a combination therapy using ThermoDox, hyperthermia and radiation. Celsion Corp. (NASDAQ:CLSN) stock price closed at $2.35 with the total traded volume of 227186 shares. Its price to sales ratio ended at 108.01. Its market capitalization is 47.01 Million. The stock owned by the Financial Institutions was 18.70% while by insiders was 11.20%.
Biopharmaceutical company, Horizon Pharma plc (NASDAQ:HZNP) released that it has filed patent infringement court cases in the U.S. District Court for the District of New Jersey related to Abbreviated New Drug Applications or ANDA filed by means of the U.S. Food and Drug Administration to market a generic version of Pennsaid or diclofenac sodium topical solution 2% w/w.The lawsuit was filed against Actavis Laboratories UT, Actavis, and Allergan plc, as well as Amneal Pharmaceuticals, LLC, IGI Laboratories, Lupin Ltd. and Lupin Pharmaceuticals, as well as Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd.The lawsuits claim infringement of Horizon’s newly issued U.S. Patent No. 9,066,913 titled “Diclofenac Topical Formulation,” which covers Pennsaid 2%. These lawsuits are the second patent litigations filed against these defendants relating to Pennsaid 2%. Horizon Pharma plc (NASDAQ:HZNP) has the market capitalization of 5.34 Billion. Shares of firm plunged -0.95% to close at $34.54 with the total traded volume of 3.09 Million. The firm has current ratio of 3.70 for the most recent quarter.
Linn Co, LLC (NASDAQ:LNCO) and LINN Energy LLC (LINE) reported that LINN has reached on a definitive contract to sell its remaining position in Howard County in the Permian Basin for a agreement price of $281M. The firms reported that the properties sold under the deal include approximately 6,400 net acres prospective for horizontal Wolfcamp drilling and approximately 2.0 MBoe/d of current production from 133 gross wells.The companies expect the transaction to close in the third quarter 2015. Linn Co, LLC (NASDAQ:LNCO) begun last trade with a price of $9.82 and throughout the trading session climbed at a high of $9.83. The day-trade ended with -3.05% to $9.53.